Ned Pagliarulo
@NedPagliarulo
Followers
5K
Following
7K
Media
814
Statuses
7K
BioPharma Dive is publishing today a database of biotech venture funding rounds. We've worked on it quite a while and think it's pretty neat. It's got charts! lists! and an interactive database that you can filter!. We'd love for you to check it out:
3
50
94
RT @ddiamond: Scoop - SUSAN MONAREZ, nation’s newly installed CDC director, is being ousted, people familiar tell @lenasun @LaurenWeberHP +….
washingtonpost.com
Susan Monarez was confirmed as the CDC’s director in July. Three top agency officials announced resignations as the Trump administration moved to oust her.
0
159
0
RT @daphnezohar: Neuropsych continuing to be a strong area for deals. Few interesting things: 1- Next gen psychedelics w/ reduced time psyc….
0
6
0
@BentheFidler Of the China out-licensing deals announced this year, many involved bispecific or trispecific antibodies, typically in oncology or immunology:.
0
1
0
Drugs from China are reshaping biotech. Track the licensing deals bringing them to the US and Europe this year, via this database from @BentheFidler: .
biopharmadive.com
Biopharmaceutical firms in the U.S. and Europe are turning to China’s biotech sector for new medicines, with licensing hitting a record pace in 2025. Follow this year’s dealmaking with this database.
2
0
3
Some background on what the deal represents, via @realJacobBell, after Bloomberg reported last month that $ABBV was in talks to buy Gilgamesh:.
0
2
2
$ABBV to acquire Gilgamesh Pharmaceuticals' lead drug, a 5-HT2A receptor agonist in testing for depression, for up to $1.2 billion:. As result of deal, Gilgamesh will spin off a new entity holding its other drug programs.
news.abbvie.com
Gilgamesh's lead asset, bretisilocin (GM-2505), is a potential best-in-class psychedelic compound currently in Phase 2 development for the treatment of major depressive disorder (MDD)....
3
3
3
RT @JMaraganore: Really important editorial from @ScottGottliebMD. “remarkably little attention is being paid to the risk that the US mi….
jamanetwork.com
This JAMA Forum discusses challenges to the US’s standing as a global leader in biomedical innovation from China, in the context of recent reductions in funding for biomedical research by the federal...
0
4
0
RT @BentheFidler: Breaking: FDA approves Ionis’ hereditary angioedema drug by @gwendolynawu $IONS $BCRX $NTLA.
biopharmadive.com
Dawnzera is the third medicine cleared by U.S. regulators this year for the rare genetic condition. Ionis set its list price at $57,462 per dose.
0
2
0
Some pharma notes in new details on US-EU trade framework:. - "Most-favored nation" tariff will apply to generics, their ingredients and chemical precursors imported from EU, from 9/1. - US will "ensure" tariff applied to pharma goods from EU doesn't >15%.
whitehouse.gov
The United States and the European Union are pleased to announce that they have agreed on a Framework on an Agreement on Reciprocal, Fair, and Balanced
0
0
2
RT @JacobPlieth: #WCLC25 late-breaker & plenary preview, via @ApexOnco $SMMT $BMY $BNTX $NUVL $CGEM.
oncologypipeline.com
Summit and Nuvalent have scored prized plenary spots.
0
11
0
RT @maxonwifi: "Going forward, speaking for myself, based on these findings, I will no longer be able to trust that what is presented in CD….
0
1
0
Kennedy’s mRNA cuts could set US science back, experts warn via @Lilah_Alvarado.
biopharmadive.com
Scientists say HHS’ decision to defund mRNA vaccine research will leave the country less prepared for pandemics, and make it harder to invest in companies advancing the technology.
1
2
2
RT @brittanytrang: OpenAI says ChatGPT isn't intended to diagnose/treat medical conditions, yet in GPT-5's launch, Sam Altman encouraged pe….
statnews.com
Why OpenAI may run into trouble with the FDA for promoting GPT-5's health advice with little supporting evidence
0
2
0
$SRPT Elevidys revenue. 2Q25 - $282mm .1Q25 - $375mm .4Q24 - $384mm.3Q24 - $181mm .2Q24 - $122mm. Recent developments with LGMD patient death, FDA hold, shipment pause occurred in July. 2Q SEC filing here:
0
1
5
RT @BentheFidler: David Altshuler, geneticist who helped transform Vertex, to retire next year $VRTX.
biopharmadive.com
Since becoming Vertex's top scientist in 2015, Altshuler has shaped the company’s efforts to expand beyond cystic fibrosis.
0
1
0
In rumored AbbVie deal, Wall Street sees momentum for psychedelics M&A via @realJacobBell.
biopharmadive.com
A potentially billion-dollar acquisition of Gilgamesh Pharmaceuticals suggests big pharma may finally be willing to place significant bets on psychedelics.
0
1
3
RT @davidalim: One notable scoop in this story: . The Trump administration is weighing splitting the FDA's Center for Biologics Evaluation….
0
7
0
RT @matthewherper: Thinking out loud, but the theme that unites the two big news stories in the medical world today is that patient advocac….
0
25
0
RT @BentheFidler: Vinay Prasad, controversial FDA official, abruptly departs agency
biopharmadive.com
Prasad's exit ends a tumultuous tenure during which he led a reworking of agency guidelines on COVID vaccines and his office got embroiled in controversy over a Duchenne gene therapy.
0
1
0